Patient Satisfaction and Quality of Life Impact - PecFent® (Qualipec)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01693328|
Recruitment Status : Unknown
Verified January 2014 by Archimedes Development Ltd.
Recruitment status was: Recruiting
First Posted : September 26, 2012
Last Update Posted : January 15, 2014
National multicenter, prospective, observational study in cancer patients with chronic background pain and breakthrough pain to whom PecFent® has been prescribed under pragmatic condition by a specialist in the treatment of cancer pain conditions.
• Study objectives include assessment of early treatment satisfaction.
|Condition or disease||Intervention/treatment|
|Breakthrough Cancer Pain||Drug: PecFent® (fentanyl) nasal spray|
|Study Type :||Observational|
|Estimated Enrollment :||300 participants|
|Official Title:||A French, Multicentre, Open-label, Observational Study to Assess Quality of Life and Satisfaction in Subjects Taking PecFent® for the Treatment of Breakthrough Cancer Pain (BTPc)|
|Study Start Date :||September 2012|
|Estimated Primary Completion Date :||March 2014|
|PecFent®||Drug: PecFent® (fentanyl) nasal spray|
- Satisfaction [ Time Frame: Satisfaction will be assessed approximately 1 hour after each BTPc episode treated with PecFent® from completion of titration through Day 7 ]Satisfaction will be assessed using a 4-point Likert scale.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01693328
|Contact: Sylvie Allouche, MDfirstname.lastname@example.org|
|Contact: Jerome Fayette, MD +33487785451 email@example.com|
|Principal Investigator: Jerome Fayette, MD|
|Principal Investigator:||Alain Serrie, MD||Head of Pain Federation - Palliative Medicine Lariboisiere Hospital, Paris France|